Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers-Reference-Cited by-同舟云学术

Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers

Published:2018-06 Issue: Volume:191 Page:10-20
ISSN:1521-6616
Container-title:Clinical Immunology
language:en
Short-container-title:Clinical Immunology

Author:

Weinhold Kent J.,Bukowski Jack F.,Brennan Todd V.,Noveck Robert J.,Staats Janet S.,Lin Liwen,Stempora Linda,Hammond Constance,Wouters Ann,Mojcik Christopher F.,Cheng John,Collinge Mark,Jesson Michael I.^ORCID,Hazra Anasuya,Biswas Pinaki,Lan Shuping,Clark James D.,Hodge Jennifer A.

Funder

Pfizer Inc.

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference39 articles.

1. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs;Fleischmann;Arthritis Rheum.,2012

2. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo;Kremer;Arthritis Rheum.,2009

3. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone;Kremer;Arthritis Rheum.,2012

4. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate;Tanaka;Arthritis Care Res.,2011

5. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study;Tanaka;Mod. Rheumatol.,2015

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors;Drug Safety;2023-07-25

2. Tofacitinib for new-onset adult patients with anti-melanoma differentiation-associated 5 gene antibody positive dermatomyositis;Clinical Rheumatology;2023-03-16

3. Current approaches to evaluate the function of cytotoxic T-cells in non-human primates;Journal of Immunotoxicology;2023-02-14

4. Janus kinase inhibitors alter NK cell phenotypes and inhibit their antitumour capacity;Rheumatology;2022-12-30

5. The roles of HDAC with IMPDH and mTOR with JAK as future targets in the treatment of rheumatoid arthritis with combination therapy;Journal of Complementary and Integrative Medicine;2022-11-21